Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
Investors betting on the Principia short thesis face up to a clinical trial success that might not be what it seems.
The academic Dian-Tu study looks at anti-amyloid beta antibodies from Lilly and Roche; despite gantenerumab, hopes are being dialled back.
A clutch of swift FDA decisions boosted average US drug approval times in 2019, helping biopharma to deliver another bumper crop of new medicines.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.